Compare Johnson & Johnson (JNJ) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Ultra Short Bond ETF — how do they compare? Johnson & Johnson trades at $261.05 (market cap $618.09B), while Vanguard Ultra Short Bond ETF trades at $49.48 (market cap $10.20B). The key difference: Johnson & Johnson is far larger — about 60.6× Vanguard Ultra Short Bond ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Ultra Short Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| JNJ | VUSB | |
|---|---|---|
Market Cap | $618.09B | $10.20B |
Volume | 6,050,983 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $278.43 | $50.03 |
52-Week Low | $186.00 | $49.41 |
Typical Hold Time | 129 Days | 61 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
